Verrica’s stock dips despite Phase 2 skin cancer drug clearing more than 50% of lesions
Verrica Pharmaceuticals’ oncolytic peptide that could help eliminate or ease the burden of surgery in basal cell carcinoma has shown signs of efficacy in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
